Disease Modifying Drugs http://msrcsharing.yuku.com/forums/7 For open discussion of DMD medicines (beta interferons and glatiramer acetate and Tysabri). For those newly prescribed, long term users or those considering their use. ]]> en-us Copyright 2006, Yuku feeds@yuku.com (FeedMaster) webmaster@yuku.com (WebMaster) Thu, 10 Dec 2009 11:42:27 GMT Yuku Feeds 1.0 http://blogs.law.harvard.edu/tech/rss 60 Yuku http://static.yuku.com//feed/bypass/images/button-yuku.png http://msrcsharing.yuku.com/forums/7 Yuku - free hosted forums and profiles 88 31 {pics-1.1 "http://www.icra.org/ratingsv02.html" l gen true for "http://yuku.com" r (nz 1 vz 1 lz 1 oz 1 cz 1 ) "http://www.rsac.org/ratingsv01.html" l gen true for "http://yuku.com" r (n 0 s 0 v 0 l 0 )) Search Search Domain q http://yuku.com/search/direct/ <![CDATA[ Betaferon® approved in China for treatment of Multiple Sclerosis ]]> http://msrcsharing.yuku.com/topic/15915/t/Betaferon-approved--China--treatment--Multiple-Sclerosis.html Betaferon®Bayer Schering Pharma AG announced that the Chinese State Food and Drug Administration (SFDA) has approved Betaferon® (interferon beta-1b) therapy for patients with feeds@yuku.com (squiffy2) http://msrcsharing.yuku.com/topic/15915 Tue, 01 Dec 2009 13:41:10 GMT <![CDATA[ Fifty percent of MS patients avoid treatment over injectable delivery fears ]]> http://msrcsharing.yuku.com/topic/15833/t/Fifty-percent--MS-patients-avoid-treatment--injectable-deliv.html Injectable MS Treatments
Around half of all multiple sclerosis (MS) patients that are eligible for treatment do not receive it and one in five of those patients that do begin therapy, delay doing so because of fear and anxiety over the treatment process, and not fear and anxiety about the disease.

These observations are according to Patricia Kennedy, a nurse practitioner... ]]> feeds@yuku.com (squiffy2) http://msrcsharing.yuku.com/topic/15833 Fri, 20 Nov 2009 08:09:33 GMT <![CDATA[ Tysabri problems - fault of European doctors? ]]> http://msrcsharing.yuku.com/topic/15650/t/Tysabri-problems-fault-of-European-doctors-.html TysabriBiogen Idec's key multiple sclerosis drug Tysabri had been linked to 23 worldwide cases of a potentially deadly brain infection called progressive multifocal leukoencephalopathy, or PML - with most confirmed cases... ]]> feeds@yuku.com (squiffy2) http://msrcsharing.yuku.com/topic/15650 Wed, 28 Oct 2009 08:51:57 GMT <![CDATA[ Review of benefits and risks for Tysabri started ]]> http://msrcsharing.yuku.com/topic/15604/t/Review-of-benefits-and-risks-for-Tysabri-started.html TysabriThe European Medicines Agency Committee for Medicinal Products for Human Use has started a review of the benefits and risks of Tysabri, in view of reports of 23 cases of progressive multifocal... ]]> feeds@yuku.com (squiffy2) http://msrcsharing.yuku.com/topic/15604 Fri, 23 Oct 2009 14:30:16 GMT <![CDATA[ Patient treated with Tysabri for Multiple Sclerosis develops brain cancer (primary central nervous system lymphoma) ]]> http://msrcsharing.yuku.com/topic/15571/t/Patient-treated--Tysabri--Multiple-Sclerosis-develops-brain-.html TysabriA case report of brain cancer (primary central nervous system lymphoma) developing in a person being treated with Tysabri® (natalizumab, Biogen Idec and Elan Pharmaceuticals) has been published. Achim Berthele, MD... ]]> feeds@yuku.com (squiffy2) http://msrcsharing.yuku.com/topic/15571 Wed, 21 Oct 2009 09:13:39 GMT <![CDATA[ Teva moves to delay Mylan Pharmaceutical's generic version of multiple sclerosis drug, Copaxone ]]> http://msrcsharing.yuku.com/topic/15549/t/Teva-moves--delay-Mylan-Pharmaceutical-s-generic-version--mu.html CopaxoneTeva Pharmaceuticals said it has filed a lawsuit to block rival drugmaker Mylan Pharmaceuticals from launching a generic version of its multiple sclerosis drug.

Mylan previously announced its intent to launch a generic version of feeds@yuku.com (squiffy2) http://msrcsharing.yuku.com/topic/15549 Mon, 19 Oct 2009 05:03:41 GMT <![CDATA[ Minocycline is proposed as an add-on therapy to improve the efficacy of glatiramer acetate (Copaxone) ]]> http://msrcsharing.yuku.com/topic/15502/t/Minocycline--proposed---add--therapy--improve--efficacy--gla.html MinocyclineSummary
Minocycline is proposed as an add-on therapy to improve the efficacy of glatiramer acetate in feeds@yuku.com (squiffy2) http://msrcsharing.yuku.com/topic/15502 Wed, 14 Oct 2009 06:32:23 GMT <![CDATA[ Copaxone can significantly delay the onset of Multiple Sclerosis in many patients with early symptoms ]]> http://msrcsharing.yuku.com/topic/15438/t/Copaxone--significantly-delay--onset--Multiple-Sclerosis---p.html CopaxoneAmong patients who show early signs of multiple sclerosis, treatment with Copaxone (glatiramer acetate) appears to halve the risk that they will develop full-blown disease, new research suggests.

About 85... ]]> feeds@yuku.com (squiffy2) http://msrcsharing.yuku.com/topic/15438 Wed, 07 Oct 2009 06:20:31 GMT <![CDATA[ A single-centre, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis ]]> http://msrcsharing.yuku.com/topic/15434/t/-single-centre-randomized-double-blind-placebo-controlled-st.html Interferon beta-1bInflammation and neurodegeneration may have differential impacts on disease evolution in the different forms of multiple sclerosis. However, a beneficial effect of immunomodulatory drugs should not be ruled out in primary... ]]> feeds@yuku.com (squiffy2) http://msrcsharing.yuku.com/topic/15434 Fri, 02 Oct 2009 05:22:55 GMT <![CDATA[ Biogen says PML risk factors still inconclusive for Tysabri ]]> http://msrcsharing.yuku.com/topic/15294/t/Biogen-says-PML-risk-factors-still-inconclusive-for-Tysabri.html TysabriBiogen Idec Inc said on Tuesday it would be premature to conclude that the risk of developing a potentially deadly brain infection increases the longer patients take its multiple sclerosis drug feeds@yuku.com (squiffy2) http://msrcsharing.yuku.com/topic/15294 Wed, 16 Sep 2009 07:34:04 GMT <![CDATA[ Biogen gets patent extension on MS drug Avonex to 2026 ]]> http://msrcsharing.yuku.com/topic/15292/t/Biogen-gets-patent-extension-on-MS-drug-Avonex-to-2026.html AvonexBiogen Idec Inc. has essentially received a 13-year patent extension on its biggest moneymaker, the multiple sclerosis drug Avonex, according to a Securities and Exchange Commission filing Tuesday.

Key... ]]> feeds@yuku.com (squiffy2) http://msrcsharing.yuku.com/topic/15292 Wed, 16 Sep 2009 07:12:29 GMT <![CDATA[ FDA approval of generic glatiramer (Capaxon R) injection for Multiple Sclerosis ]]> http://msrcsharing.yuku.com/topic/15289/t/FDA-approval--generic-glatiramer-Capaxon-R-injection--Multip.html Capaxon RIndian generic firm Natco Pharma Ltd announced US FDA approval for the multiple sclerosis drug generic glatiramer acetate injectable application filed by its partner Mylan Inc.

Last year, Natco entered... ]]> feeds@yuku.com (squiffy2) http://msrcsharing.yuku.com/topic/15289 Wed, 16 Sep 2009 06:08:50 GMT <![CDATA[ Tysabri + alcohol ]]> http://msrcsharing.yuku.com/topic/15265/t/Tysabri-alcohol.html Cheers
Anna
]]> feeds@yuku.com (sillybilly) http://msrcsharing.yuku.com/topic/15265 Sun, 13 Sep 2009 13:11:59 GMT <![CDATA[ Rapid beneficial effects of new Rebif(R) formulation on MRI outcomes in Multiple Sclerosis ]]> http://msrcsharing.yuku.com/topic/14559/t/Rapid-beneficial-effects--new-Rebif-R-formulation--MRI-outco.html Rebif

Patients with relapsing-remitting multiple sclerosis (RRMS) show early benefit from a new formulation of subcutaneous interferon (IFN) beta-1a as measured by magnetic resonance imaging (MRI), according to a study... ]]> feeds@yuku.com (squiffy2) http://msrcsharing.yuku.com/topic/14559 Wed, 24 Jun 2009 14:04:02 GMT <![CDATA[ RebiSmart(TM), first electronic injection device for delivery of Multiple Sclerosis treatment Rebif(R), launched ]]> http://msrcsharing.yuku.com/topic/14551/t/RebiSmart-TM--electronic-injection-device--delivery--Multipl.html Merck Serono Logo

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today the launch of the innovative individually adjustable electronic injection device RebiSmart(TM) for the self-administration of feeds@yuku.com (squiffy2) http://msrcsharing.yuku.com/topic/14551 Wed, 24 Jun 2009 10:13:42 GMT <![CDATA[ Continuous disease-modifying treatment without interruptions provides better long-term outcomes in Multiple Sclerosis ]]> http://msrcsharing.yuku.com/topic/14549/t/Continuous-disease-modifying-treatment--interruptions-provid.html Disease Modifying Drugs

Patients with multiple sclerosis (MS) who adhere to their treatment with interferon (IFN) beta-1a without interruption have lower relapse and progression rates than... ]]> feeds@yuku.com (squiffy2) http://msrcsharing.yuku.com/topic/14549 Wed, 24 Jun 2009 06:30:33 GMT <![CDATA[ Eighth Tysabri patient reported with PML infection ]]> http://msrcsharing.yuku.com/topic/14463/t/Eighth-Tysabri-patient-reported-with-PML-infection.html Tysabri

Biogen Idec Inc. said a patient taking its multiple sclerosis drug Tysabri was diagnosed with a life-threatening brain illness, the eighth case reported in the last year.

The patient was confirmed to have progressive multifocal leukoencephalopathy, or PML, on June 10, according to a report on Cambridge, Massachusetts-based Biogen's Web site. About 56,700... ]]> feeds@yuku.com (squiffy2) http://msrcsharing.yuku.com/topic/14463 Sun, 14 Jun 2009 14:42:15 GMT <![CDATA[ MS disease modifying drugs - are they increasing the risk of cancer? ]]> http://msrcsharing.yuku.com/topic/14257/t/MS-disease-modifying-drugs---increasing--risk--cancer-.html Disease Modifying Drugs

Current CIHR-funded research: In the first study of its kind, researchers from Canada are examining whether beta-interferon, widely used to treat multiple sclerosis (MS), increases the... ]]> feeds@yuku.com (squiffy2) http://msrcsharing.yuku.com/topic/14257 Sun, 17 May 2009 06:51:29 GMT <![CDATA[ Incidence of PML with Tysabri in Multiple Sclerosis lower than previously thought ]]> http://msrcsharing.yuku.com/topic/14135/t/Incidence--PML--Tysabri--Multiple-Sclerosis-lower--previousl.html JC Virus

The risk of developing progressive multifocal leukoencephalopathy (PML), a viral brain infection, in patients with multiple sclerosis (MS) taking the drug natalizumab (Tysabri) appears to be much lower - and the infection less deadly - than previously estimates, according to new postmarketing surveillance data.

Previous research found that the risk of... ]]> feeds@yuku.com (squiffy2) http://msrcsharing.yuku.com/topic/14135 Wed, 06 May 2009 06:16:01 GMT <![CDATA[ Combination of drugs may relieve Multiple Sclerosis symptoms ]]> http://msrcsharing.yuku.com/topic/14098/t/Combination-of-drugs-may-relieve-Multiple-Sclerosis-symptoms.html Interferon and Steroids

Adding steroid to multiple sclerosis treatment shows promise in study.

Using a steroid drug in combination with a multiple sclerosis (MS) drug may give patients more relief from feeds@yuku.com (squiffy2) http://msrcsharing.yuku.com/topic/14098 Fri, 01 May 2009 08:21:14 GMT